LMBRI, Lipopharma Therapeutics collaborate to promote cancer drug development, improve patient outcomes

LMBRI LLC and Lipopharma Therapeutics SL today announced collaboration aimed at transforming cancer drug development and improving patient outcomes. Lipopharma developed new assessment approaches, methods and technologies for developing cancer therapeutics and diagnostics using their proprietary design of structure-based molecules that regulate the structure and functions of the membrane lipids, instead targeting cellular proteins, called "Membrane Lipid-Therapy (MLT)".

Under terms of the agreement, Lipopharma is appointing LMBRI to commercialize its world-wide rights of its platform technology and products for licensing and marketing.

The companies jointly will provide lipid based drug development technology and enhancement in product pipeline to bring more effective and less toxic cancer therapeutics.

Vicenc Tur, CEO of Lipopharma Therapeutics, SL said that "we are very excited to collaborate with LMBRI with the goal to provide the US market with this new technology and approach the problem of drug development from a new perspective." He also declares that "we have chosen LMBRI as our partner in the US because of their profound knowledge of the US market and their well-regarded reputation as consultants for the biopharma industry globally."

"We have entered this collaboration with the view to bring Lipopharma's unique technology to pharmaceutical and healthcare industries in the US. This collaboration has allowed us to provide our pharmaceutical clients access to Lipopharma's innovative technology and products," says Svetlana Dey, Managing Director of LMBRI, LLC.